stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) Operating cash flow
CareDx, Inc.'s operating cash flow for fiscal 2025 was $42.0M, up 10.5% from $38.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $69.0M. Over the past ten years it has ranged from −$25.2M (fiscal 2022) to $42.0M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. CareDx, Inc. ranks 20th of 49 Diagnostics & Research companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $42.0M | 10.47% |
| FY2024 | $38.0M | — |
| FY2023 | −$18.4M | — |
| FY2022 | −$25.2M | — |
| FY2021 | −$19.3M | — |
| FY2020 | $33.4M | — |
| FY2019 | −$2.8M | — |
| FY2018 | −$4.0M | — |
| FY2017 | −$14.3M | — |
| FY2016 | −$16.5M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $12.7M | (58.44%) |
| Jun 2026 | $30.6M | 606.30% |
| Mar 2026 | $4.3M | (79.72%) |
| Dec 2025 | $21.4M | (42.82%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SHC Sotera Health Company compare | $331.6M |
| RDNT RadNet, Inc. compare | $310.1M |
| VCYT Veracyte, Inc. compare | $173.9M |
| CDNA CareDx, Inc. | $69.0M |
| BLLN BillionToOne, Inc. compare | $47.9M |
| NEO NeoGenomics, Inc. compare | $4.3M |
| ADPT Adaptive Biotechnologies Corporation compare | −$4.3M |
| WGS GeneDx Holdings Corp. compare | −$48.7M |
| GRAL GRAIL, Inc. compare | −$306.2M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement